Journal of Medicinal Chemistry,
Journal Year:
2024,
Volume and Issue:
unknown
Published: July 11, 2024
The
exploration
of
novel
anticancer
compounds
based
on
natural
cyclopeptides
has
emerged
as
a
pivotal
paradigm
in
the
contemporary
advancement
macrocyclic
pharmaceuticals.
Phakellistatin
Molecules,
Journal Year:
2021,
Volume and Issue:
26(23), P. 7109 - 7109
Published: Nov. 24, 2021
Curcumin
is
the
primary
polyphenol
in
turmeric's
curcuminoid
class.
It
has
a
wide
range
of
therapeutic
applications,
such
as
anti-inflammatory,
antioxidant,
antidiabetic,
hepatoprotective,
antibacterial,
and
anticancer
effects
against
various
cancers,
but
poor
solubility
low
bioavailability.
Objective:
To
improve
curcumin's
bioavailability,
plasma
concentration,
cellular
permeability
processes.
The
nanocurcumin
approach
over
curcumin
been
proven
appropriate
for
encapsulating
or
loading
(nanocurcumin)
to
increase
its
potential.
Conclusion:
Though
incorporating
into
form
may
be
viable
method
overcoming
intrinsic
limitations,
there
are
reasonable
concerns
regarding
toxicological
safety
once
it
enters
biological
pathways.
This
review
article
mainly
highlights
benefits
curcumin.
Journal of Experimental & Clinical Cancer Research,
Journal Year:
2023,
Volume and Issue:
42(1)
Published: Sept. 1, 2023
Tumors
have
evolved
in
various
mechanisms
to
evade
the
immune
system,
hindering
antitumor
response
and
facilitating
tumor
progression.
Immunotherapy
has
become
a
potential
treatment
strategy
specific
different
cancer
types
by
utilizing
multifarious
molecular
enhance
against
tumors.
Among
these
mechanisms,
ubiquitin-proteasome
system
(UPS)
is
significant
non-lysosomal
pathway
protein
degradation,
regulated
deubiquitinating
enzymes
(DUBs)
that
counterbalance
ubiquitin
signaling.
Ubiquitin-specific
proteases
(USPs),
largest
DUB
family
with
strongest
variety,
play
critical
roles
modulating
cell
function,
regulating
response,
participating
antigen
processing
presentation
during
According
recent
studies,
expressions
of
some
USP
members
cells
are
involved
escape
microenvironment.
This
review
explores
targeting
USPs
as
new
approach
for
immunotherapy,
highlighting
basic
preclinical
studies
investigating
applications
inhibitors.
By
providing
insights
into
structure
function
immunity,
this
aims
at
assisting
developing
therapeutic
approaches
enhancing
immunotherapy
efficacy.
Molecular Cancer,
Journal Year:
2022,
Volume and Issue:
21(1)
Published: July 15, 2022
Increasing
evidence
has
demonstrated
that
circular
RNAs
(circRNAs)
are
implicated
in
cancer
progression.
However,
the
aberrant
expression
and
biological
functions
of
circRNAs
clear
cell
renal
carcinoma
(cRCC)
remain
largely
elusive.Differentially
expressed
cRCC
were
filtered
via
bioinformatics
analysis.
Aberrant
circPOLR2A
was
validated
tissues
lines
qRT-PCR.
Sanger
sequencing
used
to
identify
backsplicing
site
circPOLR2A.
In
vitro
vivo
functional
experiments
performed
evaluate
role
malignancy.
RNA
pull-down,
mass
spectrometry,
RIP,
FISH
immunofluorescence
assays
validate
circPOLR2A-interacting
proteins.
Ubiquitination
modification
interaction
between
proteins
detected
Co-IP
western
blotting.
The
m6A
by
meRIP
assay.Bioinformatics
analysis
revealed
highly
metastatic
tissues.
CircPOLR2A
associated
with
tumor
size
TNM
stage
patients.
accelerated
proliferation,
migration,
invasion
angiogenesis,
while
inhibiting
apoptosis.
Further
mechanistic
research
suggested
could
interact
UBE3C
PEBP1
proteins,
act
as
a
specific
ubiquitin
E3
ligase
for
protein.
UBE3C/circPOLR2A/PEBP1
protein-RNA
ternary
complex
enhanced
UBE3C-mediated
ubiquitination
degradation
protein
which
inactivate
ERK
signaling
pathway.
Rescue
downstream
target
Furthermore,
confirmed,
reader
YTHDF2
regulate
expression.Our
study
modulated
protein,
further
activated
pathway
during
progression
metastasis.
reader,
YTHDF2,
regulated
cRCC.
Hence,
be
potential
diagnosis
treatment
Frontiers in Immunology,
Journal Year:
2022,
Volume and Issue:
13
Published: July 20, 2022
Regulation
of
ubiquitination
is
involved
in
various
processes
cancer
occurrence
and
development,
including
cell
cycle
arrest,
proliferation,
apoptosis,
invasion,
metastasis,
immunity.
Ubiquitination
plays
an
important
role
not
only
at
the
transcriptional
post-translational
levels
but
also
protein
level.
When
a
pathological
state,
abnormally
activated
biological
will
induce
progression
immune
evasion.
The
main
function
deubiquitinases
(DUBs)
to
remove
ubiquitin
chains
from
substrates,
changing
activity
substrates.
It
has
great
potential
improve
prognosis
by
targeting
DUB
regulate
proteome.
Ubiquitin-specific
peptidase
22
(USP22)
belongs
ubiquitin-specific
protease
(USP)
family
DUBs
been
reported
be
related
physiological
processes.
USP22
expressed
malignant
tumors
such
as
prostate
cancer,
lung
liver
colorectal
which
suggests
that
may
play
tumors.
stabilize
programmed
death
ligand
1
(PD-L1)
deubiquitination
while
regulating
T-cell
infiltration
into
Regulatory
T
cells
(Tregs)
are
unique
class
immunosuppressive
CD4
+
primarily
suppress
system
expressing
master
transcription
factor
forkhead
box
3
(FOXP3).
was
found
positive
regulator
stable
FOXP3
expression.
Treg-specific
ablation
leads
reduced
tumor
volume
multiple
models.
This
resistance
immunotherapy.
In
this
article,
we
review
summarize
functions
signal
transduction
pathways
during
tumorigenesis,
evasion,
drug
resistance.
Furthermore,
propose
new
possibility
combining
with
chemotherapeutic,
targeted,
drugs
treatment
cancer.
Cells,
Journal Year:
2023,
Volume and Issue:
13(1), P. 29 - 29
Published: Dec. 22, 2023
Ubiquitination
is
a
reversible
post-translational
modification
based
on
the
chemical
addition
of
ubiquitin
to
proteins
with
regulatory
effects
various
signaling
pathways.
can
alter
molecular
functions
tagged
substrates
respect
protein
turnover,
biological
activity,
subcellular
localization
or
protein–protein
interaction.
As
result,
wide
variety
cellular
processes
are
under
ubiquitination-mediated
control,
contributing
maintenance
homeostasis.
It
follows
that
dysregulation
ubiquitination
reactions
plays
relevant
role
in
pathogenic
states
human
diseases
such
as
neurodegenerative
diseases,
immune-related
pathologies
and
cancer.
In
recent
decades,
enzymes
ubiquitin–proteasome
system
(UPS),
including
E3
ligases
deubiquitinases
(DUBs),
have
attracted
attention
novel
druggable
targets
for
development
new
anticancer
therapeutic
approaches.
This
perspective
article
summarizes
peculiarities
shared
by
involved
reaction
which,
when
deregulated,
lead
tumorigenesis.
Accordingly,
an
overview
main
pharmacological
interventions
targeting
UPS
clinical
use
still
trials
provided,
also
highlighting
limitations
efficacy
these
Therefore,
attempts
circumvent
drug
resistance
side
well
UPS-related
emerging
technologies
therapeutics
discussed.